223 related articles for article (PubMed ID: 27627731)
1. Cost-effectiveness of Intensive Blood Pressure Management.
Richman IB; Fairley M; Jørgensen ME; Schuler A; Owens DK; Goldhaber-Fiebert JD
JAMA Cardiol; 2016 Nov; 1(8):872-879. PubMed ID: 27627731
[TBL] [Abstract][Full Text] [Related]
2. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.
Bress AP; Bellows BK; King JB; Hess R; Beddhu S; Zhang Z; Berlowitz DR; Conroy MB; Fine L; Oparil S; Morisky DE; Kazis LE; Ruiz-Negrón N; Powell J; Tamariz L; Whittle J; Wright JT; Supiano MA; Cheung AK; Weintraub WS; Moran AE;
N Engl J Med; 2017 Aug; 377(8):745-755. PubMed ID: 28834469
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
[TBL] [Abstract][Full Text] [Related]
5. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
[TBL] [Abstract][Full Text] [Related]
6. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
[TBL] [Abstract][Full Text] [Related]
7. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
[TBL] [Abstract][Full Text] [Related]
10. Impact of the SPRINT Trial on Hypertension Management.
Ghazi L; Oparil S
Annu Rev Med; 2018 Jan; 69():81-95. PubMed ID: 29414255
[TBL] [Abstract][Full Text] [Related]
11. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
[TBL] [Abstract][Full Text] [Related]
12. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus.
Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM
Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops.
Bryant KB; Moran AE; Kazi DS; Zhang Y; Penko J; Ruiz-Negrón N; Coxson P; Blyler CA; Lynch K; Cohen LP; Tajeu GS; Fontil V; Moy NB; Ebinger JE; Rader F; Bibbins-Domingo K; Bellows BK
Circulation; 2021 Jun; 143(24):2384-2394. PubMed ID: 33855861
[TBL] [Abstract][Full Text] [Related]
15. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.
Williamson JD; Supiano MA; Applegate WB; Berlowitz DR; Campbell RC; Chertow GM; Fine LJ; Haley WE; Hawfield AT; Ix JH; Kitzman DW; Kostis JB; Krousel-Wood MA; Launer LJ; Oparil S; Rodriguez CJ; Roumie CL; Shorr RI; Sink KM; Wadley VG; Whelton PK; Whittle J; Woolard NF; Wright JT; Pajewski NM;
JAMA; 2016 Jun; 315(24):2673-82. PubMed ID: 27195814
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
[TBL] [Abstract][Full Text] [Related]
17. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study.
Constanti M; Floyd CN; Glover M; Boffa R; Wierzbicki AS; McManus RJ
Hypertension; 2021 Feb; 77(2):682-691. PubMed ID: 33342242
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
Lubitz CC; Economopoulos KP; Sy S; Johanson C; Kunzel HE; Reincke M; Gazelle GS; Weinstein MC; Gaziano TA
Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):621-30. PubMed ID: 26555126
[TBL] [Abstract][Full Text] [Related]
20. [The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control].
Widimský J
Vnitr Lek; 2016 Jan; 62(1):44-7. PubMed ID: 26967236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]